全文获取类型
收费全文 | 44173篇 |
免费 | 3342篇 |
国内免费 | 178篇 |
专业分类
耳鼻咽喉 | 332篇 |
儿科学 | 1240篇 |
妇产科学 | 936篇 |
基础医学 | 5723篇 |
口腔科学 | 746篇 |
临床医学 | 4532篇 |
内科学 | 9794篇 |
皮肤病学 | 647篇 |
神经病学 | 4441篇 |
特种医学 | 1457篇 |
外国民族医学 | 1篇 |
外科学 | 6182篇 |
综合类 | 729篇 |
一般理论 | 32篇 |
预防医学 | 3884篇 |
眼科学 | 784篇 |
药学 | 3145篇 |
1篇 | |
中国医学 | 55篇 |
肿瘤学 | 3032篇 |
出版年
2023年 | 236篇 |
2022年 | 306篇 |
2021年 | 807篇 |
2020年 | 554篇 |
2019年 | 802篇 |
2018年 | 929篇 |
2017年 | 735篇 |
2016年 | 755篇 |
2015年 | 926篇 |
2014年 | 1317篇 |
2013年 | 1862篇 |
2012年 | 2783篇 |
2011年 | 3107篇 |
2010年 | 1700篇 |
2009年 | 1553篇 |
2008年 | 2621篇 |
2007年 | 2877篇 |
2006年 | 2742篇 |
2005年 | 2821篇 |
2004年 | 2605篇 |
2003年 | 2480篇 |
2002年 | 2284篇 |
2001年 | 628篇 |
2000年 | 529篇 |
1999年 | 641篇 |
1998年 | 541篇 |
1997年 | 421篇 |
1996年 | 418篇 |
1995年 | 359篇 |
1994年 | 316篇 |
1993年 | 336篇 |
1992年 | 433篇 |
1991年 | 415篇 |
1990年 | 388篇 |
1989年 | 317篇 |
1988年 | 314篇 |
1987年 | 286篇 |
1986年 | 258篇 |
1985年 | 308篇 |
1984年 | 358篇 |
1983年 | 291篇 |
1982年 | 302篇 |
1981年 | 297篇 |
1980年 | 274篇 |
1979年 | 196篇 |
1978年 | 190篇 |
1977年 | 175篇 |
1976年 | 156篇 |
1974年 | 160篇 |
1973年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
11.
12.
13.
14.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study 下载免费PDF全文
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
15.
Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged. 相似文献
16.
17.
18.
19.
20.
Philip A. Rozario Nancy L. Morrow-Howell Enola K. Proctor 《Quality of life research》2006,15(4):755-759
Using the SF-12 to measure physical and mental functioning, the authors examine the intra-individual changes in health-related
quality of life (HRQOL) 6 months post-discharge for depressed older adults. In addition, they examine three sets of predictors
that might influence these changes. The sample of depressed older adults was recruited from an inpatient geropsychiatry unit.
Although their physical and mental health scores on the SF-12 were lower than comparable norms, the sample showed an average
increase in their mental functioning but a decrease in the physical functioning over the 6 months. Negative life-events were
significant predictors of people who reported no change in their mental health functioning and decreases in their physical
health functioning. Interestingly, those who experienced positive life events were more likely to report declines and younger
participants were more likely to report no change in their physical functioning. The findings indicate that the effects of
depression on HRQOL can have enduring effects on a sample of previously hospitalized older adults. The significance of life
event changes might signify the importance of taking into account non-traditional areas of medical interventions. Further,
the findings indicate the usefulness of the SF-12 quantifying HRQOL outcomes. 相似文献